Literature DB >> 12545139

A rational approach for selection of optimal covariate-based dosing strategies.

Siv Jönsson1, Mats O Karlsson.   

Abstract

BACKGROUND: At present, there is no rational approach for choosing a dosing strategy for individualization based on a covariate. An approach to use in establishment of an a priori dosing strategy for individualization is presented. Factors influencing the choice of such a dosing strategy are identified.
METHODS: The approach requires definition of the following: target variable, seriousness of deviations from the target (ie, risk function), population model, covariate distributions, and constraints. Minimizing the total risk yields an optimal dosing strategy, estimated as dose sizes for different subpopulations and covariate cutoff values at which doses are increased or decreased. The method was illustrated with the use of simulated and real drug examples for the situation in which clearance is related to creatinine clearance.
RESULTS: The estimated optimal cutoff(s) paralleled the median creatinine clearance in the population. The extent of variability in clearance explained by creatinine clearance was the main factor influencing the optimal ratios between adjacent dose sizes. An optimal dosing strategy was possible to estimate for the real drug.
CONCLUSIONS: The method is simple to perform, although one difficulty lies in defining the target variable and risk function. Our results imply that commonly used constraints in dosing strategies based on renal function (ie, dose ratio of 2 and predetermined cutoffs) are nonoptimal in the sense we propose. Because an optimal dosing strategy may not be practical to use, the therapeutic cost that would result with any constraint can be assessed by comparison of the outcome after the desired and the optimal strategy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12545139     DOI: 10.1067/mcp.2003.2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Authors:  Siv Jönsson; Yi-Fang Cheng; Charlotte Edenius; Kennedy R Lees; Tomas Odergren; Mats O Karlsson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study.

Authors:  A Rao; J F Standing; S Naik; M O Savage; I R Sanderson
Journal:  BMJ Open       Date:  2013-05-28       Impact factor: 2.692

3.  Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Authors:  Elin M Svensson; Gunnar Yngman; Paolo Denti; Helen McIlleron; Maria C Kjellsson; Mats O Karlsson
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

Review 4.  Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.

Authors:  Daniel Gonzalez; Gauri G Rao; Stacy C Bailey; Kim L R Brouwer; Yanguang Cao; Daniel J Crona; Angela D M Kashuba; Craig R Lee; Kathryn Morbitzer; J Herbert Patterson; Tim Wiltshire; Jon Easter; Scott W Savage; J Robert Powell
Journal:  Clin Transl Sci       Date:  2017-08-10       Impact factor: 4.689

5.  Dose banding - Weighing up benefits, risks and therapeutic failure.

Authors:  Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2022-03-24       Impact factor: 3.716

6.  Optimal control for colistin dosage selection.

Authors:  Aline Vidal Lacerda Gontijo; André V G Cavalieri
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-22       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.